...
首页> 外文期刊>Clinical and experimental medicine >Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation
【24h】

Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation

机译:血浆凝块形成和凝块裂解,以比较不同抗凝治疗对心房颤动患者止血的影响

获取原文
获取原文并翻译 | 示例

摘要

The effect of direct oral anticoagulants (DOACs) on turbidimetric measurements of plasma clot formation and susceptibility to fibrinolysis may facilitate a comparison between different classes of anticoagulants in plasma samples. We obtained 424 citrate plasma samples from 226 atrial fibrillation patients on anticoagulation and 24 samples without anticoagulation serving as controls. As comparators, we measured the international normalized ratio (INR) for phenprocoumon samples (N = 166), anti-Xa for low molecular weight heparin (LMWH) samples (N = 42), and DOAC levels with mass spectrometry (dabigatran N = 40, rivaroxaban N = 110, apixaban N = 42). Plasma clot formation and lysis were recorded continuously on a photometer after addition of an activation mix (tissue factor 2 pmol/l and tissue plasminogen activator 333 ng/ml). We used linear regression and ANCOVA for correlation analysis. Clot formation lag phase was prolonged in the presence of anticoagulants in a concentration-dependent manner for DOACs (dabigatran Spearman r = 0.74; rivaroxaban r = 0.78; apixaban r = 0.72, all p 0.0001), INR dependent for phenprocoumon (r = 0.59, p 0.0001), anti-Xa level dependent in LMWH samples (r = 0.90, p 0.0001). Maximum rate of clot formation and peak clot turbidity were reduced in the presence of anticoagulants, but correlated only moderately with the comparator measures of anticoagulation. The clot lysis time was inversely correlated with DOAC concentrations in the presence of recombinant thrombomodulin. A direct ex vivo comparison between the effects of different classes of anticoagulants is possible with turbidimetric measurement of plasma clot formation and lysis. Anticoagulation inhibited clot formation in a plasma concentration manner for DOACs, INR dependent for phenprocoumon, and anti-Xa dependent for LMWH. Susceptibility to fibrinolysis increased with increasing DOAC concentrations.
机译:直接口服抗凝血剂(DOAC)对血浆凝块形成和纤维蛋白溶解敏感性的浊度测量的影响可以促进不同类别抗凝血剂在血浆样品中的比较。我们从226例心房颤动患者获得424个柠檬酸盐等离子体样品,抗凝血患者和24个样品,没有抗凝血作为对照。作为比较器,我们测量了诸如Phenprocoumon样品(n = 166)的国际标准化比(INR),用于低分子量肝素(LMWH)样品(n = 42)的抗XA,以及具有质谱法的DOAC水平(Dabigatran n = 40 ,rivaroxaban n = 110,apixaban n = 42)。在加入激活混合物(组织因子2pmol / L和组织纤溶酶原333ng / ml)之后,在光度计上连续记录血浆凝块形成和裂解。我们使用线性回归和Ancova进行相关分析。凝块形成滞后期以浓度依赖于DoAC的浓度依赖性方式延长(Dabigatran Spearman r = 0.74; rivaroxaban r = 0.78; Apixaban r = 0.72,所有P <0.0001),INR依赖于诸如PhenProcoumon(R = 0.59,p& 0.0001),抗XA水平依赖于LMWH样品(r = 0.90,p <0.0001)。在抗凝血剂存在下降低了凝块形成和峰凝结浊度的最大速率,但在抗凝器的比较器测量中,仅具有适度的抗凝剂测量。在重组血栓调节蛋白存在下,凝块裂解时间与DOAC浓度相反。不同类别抗凝血剂的效果之间的直接exvivo比较是可能的血浆凝块形成和裂解的浊度测量。抗凝血抑制凝块形成以血浆浓度方式用于DOACS,INR依赖于苯处理,依赖于LMWH的抗XA。随着DOAC浓度的增加,对纤维蛋白溶解的敏感性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号